Synteract

Name

Synteract

Website

https://synteract.com

Company type

Private

Founded year

1986

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Synteract is a full-service Contract Research Organization (CRO) focused on serving the emerging biopharma segment. Founded in 1986 and now operating as a Syneos Health company, it delivers clinical research services from its Morrisville, US base.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Functional Service Providers (FSP) & Resourcing CROs (HLAGAAAM)

Keywords

• Clinical research services
• Contract research organization
• Biopharma development
• Clinical trial management
• Regulatory affairs services

Headquarters

HQ city

Morrisville

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations

Core offering

Synteract is a full-service contract research organization (CRO) providing clinical research and development services to the emerging biopharma segment. The company supports drug development sponsors across clinical trial design, execution, and regulatory activities. It operates as part of Syneos Health, extending CRO capabilities across the biopharmaceutical development lifecycle.

Differentiator

Problem solved

Functional benefit

Products and services

• Full-Service CRO Services End-to-end clinical research and development services for emerging biopharma sponsors, covering clinical trial management and related drug development support activities.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Broad incumbents

• Charles River Laboratories: Diversified CRO/preclinical services company with a clinical services segment overlapping Synteract's emerging-biopharma clinical trial offering, though most of its revenue is preclinical/manufacturing.
• Parexel: Large global CRO with strong emerging-biopharma and biopharma-services franchises. Comparable service portfolio (full-service clinical, FSP, biopharma-focused) at significantly larger scale.
• PPD (Thermo Fisher Scientific): Major clinical CRO now operating inside Thermo Fisher; directly overlaps Synteract's Phase I–IV clinical delivery and emerging-biopharma focus, but at vastly larger scale.
• ICON plc: One of the largest global CROs post-PRA acquisition. Comparable to Synteract as a clinical CRO serving biopharma across all phases, though materially larger and broader in scope.
• IQVIA: The largest global CRO/biopharma services platform with significant emerging-biopharma exposure. Comparable at the service-line level (clinical trials, FSP) but competes as a much broader incumbent.

Direct peers

• Clinipace Worldwide: Mid-sized, technology-forward CRO historically focused on small and mid-sized biopharma sponsors. Highly comparable in target customer, geographic reach, and full-service clinical positioning.
• Medpace: Mid-sized, full-service clinical CRO with a reputation for serving small and mid-sized biopharma sponsors. Directly comparable in target customer (emerging biopharma), therapeutic-area breadth, and mid-tier headcount profile.
• Worldwide Clinical Trials: Mid-sized, therapeutically focused CRO explicitly targeting mid- and small-cap biopharma. Comparable to Synteract in customer segment, study-phase focus (Phases I–IV), and mid-tier operating footprint.

Emerging players

• Celerion: Specialty early-phase clinical CRO strong in first-in-human and PK/biopharm work. Comparable as a niche biopharma-focused CRO, particularly in Phase I/early clinical — an adjacent segment Synteract covers.
• WuXi AppTec / WuXi Clinical: Global CRO/CDMO with an actively growing clinical services arm serving biotech sponsors. Comparable as a clinical CRO targeting biopharma, with particular overlap on China/U.S. cross-region trials.

Market position

Customer concentration

• Xx.com/Synteract

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synteract